HONOR VIEW 20: New smartphone now on sale


This year looks to be a promising one for the smartphone, with several new models planned for launch in the next few months or being readied in the pipeline. One such smartphone, the sleek and admirably-designed Honor View 20, which has already been hailed as the ‘most beautiful (Honor) phone yet’ by the site TechAdvisor.co.uk, was launched just this past 22nd January, and is now on widespread sale and contracts in the UK.


The View 20, an Android offering made under the Honor brand name of China’s flavour-of-the-month phone manufacturer Huawei, was in fact the first new phone launch of 2019, and comes packed with an attention catching 48 megapixel camera, 256 GB worth of storage, 6.4″ IPS LCD display, sleek body design and an ‘all-over’ screen which reaches right to the edge, or bezel, of the phone. Some more features are detailed below, courtesy of the manufacturer.

  • It has a resolution of 1080×2310 and a screen size of 6.4 inches in length. The screen comes with a curved display across phone’s side. It is easy to handle. The phone uses advanced touch-screen technologies for accuracy and responsiveness. You may change the touch sensitivity on the Settings.
  • The phone comes with 4,000mAh battery with fast charging capabilities. The charge port is a USB-C. It can manipulate priority of background apps for better battery conservation. A full charge requires 1hr 12 mins of charging time.
  • Gradient effect and glass back finish. Available in blue, red and black colours. The cover can be changed whenever you want. The back finish includes a chevron design pointing downwards.
  • Storage goes up to 256 GB and RAM up to 8 GB. Unlike many high storage devices which are costly, Honor View 20 seems to be the best for its price.
  • Honor View 20 comes with flashy designs. It has a very good library of default themes and wallpapers. You get to choose the brightness, contrasts and saturation of the screen. It offers a colour wheel for more colour choices.
  • Cameras are well set; a rear camera of 48 MP with 3D camera feature. Front camera reaches to 25 MP. You can shoot 2x zoom images in very high resolutions. The Camera features a range of filters and effects including an Aperture mode for better photography.
  • You will need a 3.5mm headphone for the new smartphone. It supports mobile Bluetooth devices as well.

The phone is now on sale in Britain for the RRP of £499.-, and is also been promoted in India and China. As of the time of publishing, the phone has not yet being made available in the United States. The phone, with its dense array of improved and ground-breaking features, is being particularly aimed at amateur photographers, YouTube fans and online gamers. It has also been receiving rave reviews in the first few weeks of sale, and is being tipped as a strong competitor against other premium ‘flagship’ phones like the Samsung S10, iPhone X and OnePlus 6T.


“Honor View 20 – the new smartphone” – Aspers Casino via journalism.co.uk (6 February 2019) https://www.journalism.co.uk/press-releases/honor-view-20-the-new-smartphone/s66/a734294/


“HONOR View 20 6GB RAM 128GB” – Carphone Warehouse https://www.carphonewarehouse.com/honor/view-20-6gb-ram.deal.html?cid=PAIDSEARCH_Google_1684735579_69270255087_pla-618603948436&gclid=Cj0KCQiAtP_iBRDGARIsAEWJA8iSK4sNeqoYwoHNfsC36RlEHyKbheiVVq78RUArERIGaHfJL0WwkXoaAqz_EALw_wcB&gclsrc=aw.ds#!propsId=21507047


MOVEMBER: UK charity launches annual moustache-growing drive to fight cancer


British charity The Movember Foundation has launched its yearly Movember campaign to highlight its war on prostate cancer, which claims the lives of 11,000 men a year in the UK and will affect one in eight British males, according to figures by Prostate Cancer UK.

Every November, men are encouraged to grow moustaches in any style they choose to help raise money to help fight cancer, as well as partake in other fundraising activities. The Movember campaign has broadened its scope in recent years from prostate  cancer to increasing awareness in men’s general health, mental illness, testicular cancer and suicide prevention.


The Movember Foundation is also encouraging participants to commit to walking, running or jogging sixty kilometres in November 2018, with each kilometre representing one of the sixty men who take their lives every hour in the UK. The charity is also supporting Mo-ments, fundraising occasions that men and women can organise and host.

The charity aims to use the funds from Movember to support men recovering from cancers of the reproductive system, formulate new mental health approaches to prevent the high rate of suicides nationally among young men and healthcare campaigns for males to live longer and healthier lives.

Supporters of the campaign, informally known as Mo Bros and Mo Sistas, have become a distinctive presence in offices across the country, with the charity’s moustache logo now being highly recognised. This year’s November is being partnered with leading men’s products sellers Gillette and L’Oreal Men Expert alongside gym chain The Gym. The Movember campaign is also being supported by Prostate Cancer UK, the country’s leading research NGO into this dangerous form of the illness.

Movember is a worldwide movement, also taking place in the US, Australia, Canada, New Zealand and Spain. In 2014, 700,000 Mo Bros and Mo Sistas took part.


Movember Foundation UK, Facebook, Facebook Inc. https://www.facebook.com/MovemberUK/

“Movember United Kingdom – Home” – Movember Europe https://uk.movember.com/?utm_medium=social_paidl&utm_source=facebook&utm_campaign=Global_Signup_2018&fbclid=IwAR2l0Y2smzUKwV_g4M0VlC45a16b5zc6BU2N571fJEiQO7wqeudOT6o42Xg


“File:Movember (8140182094).jpg” – Eva Rinaldi and Movember via Wikimedia Commons (31 October 2012) https://commons.wikimedia.org/wiki/File:Movember_(8140182094).jpg

GSK CHINA CONTROVERSY: British PM risks ‘diplomatic tensions’

As the United Kingdom government prepares for a trade mission visiting China to woo the country’s investors to trade with Britain, a controversy involving a British company threatens to destabilise relations between the U.K. and China, overshadowing the upcoming visit. The international pharmaceutical giant GlaxoSmithKline (GSK) is currently under investigation by the Chinese government over alleged accusations that it behaved like a ‘criminal godfather’ in an expansive network of bribes and kickbacks.

The British Prime Minister David Cameron has stepped into the debacle by inviting the GSK chief executive officer Andrew Witty to join his delegation on the trade mission to the People’s Republic. Cameron’s invitation to Witty has raised concerns in some quarters that relations between Britain and China could degenerate if Witty participates in the mission, according to an article published today by the Huffington Post blog and news magazine. 

GlaxoSmithKline (Photo credit: Ian Wilson)

The offices of GSK in Brentford, Middlesex, UK. One of the company’s main management offices in Britain.

GSK’s Chinese division, which employs a workforce of around 7,000, was placed under investigation in July 2013 over allegations that it behaved as a Mafia godfather, using its prominence in the Chinese drugs market to act as the ringleader of a nationwide medicines bribery network. The manufacturer is accused of channelling up to 3 billion yuan (£303 million) to several doctors, hospitals and clinics to boost its drug sales and rig the country’s pharma market in its favour. The bribery operations are believed to have run since 2007.

In an investigation lasting six months, Chinese police uncovered 700 middlemen who operated via GSK and transferred funds to hospitals and medical staff to encourage them to only prescribe GSK’s drugs to patients. The money was funnelled through a series of bogus travel agencies and consultancies, according to Chinese investigators. Middlemen would bribe senior GSK executives with favours, including alleged ‘sexual kickbacks’ and cash bribes, to win trading privileges. Doctors involved in the bribery network would be issued with special credit cards tied to GSK business accounts. The doctors would then collect financial incentives to prescribe GSK drugs rather than generics or products of rival manufacturers. One travel agency suspected by police to have links to the GSK bribery network never sold any airline tickets or holiday packages but still had a turnover of tens of millions of yuan. One Chinese newspaper claimed that the agencies would set up fictitious corporate meetings that required staff travel. The budgets for these meetings that were officially meant to go on staff travel expenses were taken off-book and used to line corrupt medical professionals’ pockets.

Four senior Chinese members of GSK’s staff have already been detained and the head of Chinese operations for GSK’s headquarters in the UK has left the country and not returned, according to The Telegraph newspaper. GSK has also been investigated over tax irregularities concerning its drug sales.

Gao Feng, head of the economic crimes investigation unit at the Ministry of Public Security, has expressed publicly the controversial belief among Chinese lawmakers that bribery is an ingrained part of GSK’s business dealings. Feng said in July: “From our investigation, bribery is part of the strategy of this company. This is why they have bribery activities in China.

They used travel agents as a money platform. But I must make it clear that among these partners, GSK is the main party responsible. It is like a criminal organisation, there is always a boss. In this game, GSK is the godfather.

The investigators also claim that requests for information from GSK’s British headquarters have met with no response. Feng also stated then that similar bribery networks set up by other international pharmaceutical firms operating in China could also be uncovered by the police and ministerial investigation. Chinese patients have to pay up to 300 yuan for tablets that cost only 30 yuan to manufacture.

(c) Tom Varco/Wikimedia Commons

Andrew Witty is not only CEO of GlaxoSmithKline but also a business confidante of the British prime minister. He serves as a member of Cameron’s business advisory group. In response to the Chinese probe into his company’s financial dealings, Witty sent head of emerging markets Abbas Hussain to manage GSK’s response to the authorities’ accusations. The probe is expected to be completed this month.

GSK’s drug sales in the growing Asian superpower have plummeted since the probe began with a decline of 61%, which Witty has blamed on ‘scaremongering’ by the Chinese media. Last year, GSK made sales revenues of £759 million through pharmaceuticals and vaccines and had sustained a year-on-year increase in profitability in China’s rapidly growing medicines market, until Chinese consumers’ confidence in GSK was dampened by strong local media coverage of the scandal.

In response to the allegations, Witty said: “The activities described by the authorities are very serious and totally unacceptable. They are contrary to our values and to everything I believe in. We very clearly recognise there is a profound need to earn the trust of Chinese people again. We will take every action to do so.

We continue to fully co-operate with the authorities and respect the progress of the investigation. As such there is very little further I can say.

Earlier in July, GSK had promised full co-operation with authorities including closing down the travel agencies and conducting a ‘thorough review’ of all historic transactions conducted via the agencies and medics. An unidentified GSK spokesperson said “GSK shares the desire of the Chinese authorities to root out corruption. These allegations are shameful and we regret this has occurred“. The company has carried out a prior investigation internally into its financial practices and has found no evidence of wrongdoing or corruption, and promised to co-operate fully with the Chinese police.

RELATED NEWS from Zemanta

Half-Eaten Mind on Twitter LINK
HuffPost UK on Twitter LINK
“GSK CEO Andrew Witty Joins David Cameron In China Amid Bribery Probe” – Asa Bennett, The Huffington Post UK/AOL (UK) Limited/HPMG News (2 December 2013) LINK
“GlaxoSmithKline accused of ‘criminal godfather’ behaviour in China” – Malcolm Moore, The Telegraph via Yahoo! Finance UK & Ireland/Yahoo! – News Network (15 July 2013) LINK
“File:Lexapro pills.jpg” – Tom Varco, Wikimedia Commons (8 August 2006) LINK